**Cost-effectiveness of Enhanced Liver Fibrosis test to assess liver fibrosis in chronic HCV and ALD patients**

­Supplementary material – Utilities and costs

**Table S1**. Utilities

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **Baseline** | **Range** | **PSA distribution\*** | **Source** |
| F0-F1 | 0.77 | 0.74−0.80 | U(0.74;0.80) | [22] |
| SVR with F0-F1 | 0.82 | 0.77−0.87 | U(0.77;0.87) | [22] |
| F2-F3 | 0.66 | 0.60−0.72 | U(0.60;0.72) | [22] |
| SVR with F2-F3 | 0.72 | 0.61−0.83 | U(0.61;0.83) | [22] |
| F4 | 0.55 | 0.44−0.66 | U(0.44;0.66) | [22] |
| SVR with F4 | 0.60 | – | – | [22] |
| DC | 0.45 | – | – | [22] |
| HCC | 0.45 | – | – | [22] |
| LTX | 0.45 | – | – | Assumption |
| Post-LTX | 0.67 | – | – | [22] |
| Death | 0.0 | – | – | Assumption |
| Utility decrement if nonfatal adverse events related to biopsy | 0.20 | 0.10−0.25 | U(0.10;0.25) | [23] |
| Utility decrement during treatment with antivirals | 0.11 | – | – | [22] |
| Note: Same utilities for ALD model (SVR states correspond to abstinence states in ALD model)  F0-F1: no fibrosis or mild fibrosis; F2-F3: moderate or severe fibrosis; F4: cirrhosis; DC: decompensated cirrhosis; HCC: hepatocellular carcinoma; LTX: liver transplantation. SVR: sustained virological response.  \* PSA: probabilistic sensitivity analysis. In uniform (U) distributions, parameters correspond to minimum and maximum values. | | | | |

**Table S2**. Unit costs

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cost item** | **Baseline (€)** | **Range** | **PSA distribution\*** | **Source** |
| **Health States (annual cost)** |  |  |  |  |
| F0-F1 | 279 | – | – | [18] |
| F0-F1 and SVR | 114 |  |  | [18] |
| F2-F3 | 279 |  |  | [18] |
| F2-F3 and SVR | 114 |  |  | [18] |
| F4 | 408 |  |  | [18] |
| F4 and SVR | 165 |  |  | [18] |
| DC | 1320 |  |  | [18] |
| HCC | 4850 |  |  | [18] |
| Post-LTX | 4268 |  |  | [18] |
| Death | 0 |  |  | Assumption |
|  |  |  |  |  |
| **Transition costs** |  |  |  |  |
| To DC | 3505 | – | – | [37] |
| To HCC | 7155 |  |  | [37] |
| LTX | 68904 |  |  | [37] |
|  |  |  |  |  |
| **Treatment costs** |  |  |  |  |
| Sofosbuvir + Ledipasvir (12w) | 47000 | 25000−72000 | γ(47000;21020) | [38] |
| Alcohol detoxification therapy | 518 | 173−1036 | γ(518;232) | HCB |
|  |  |  |  |  |
| **Unit cost of tests** |  |  |  |  |
| ELF | 84.6 | 63−126 | γ(84.6;38) | HCB |
| LSM | 80 | 60−120 | γ(80;36) | HCB |
| Biopsy | 429 | 322−644 | γ(429;192) | HCB |
| F0-F1: no fibrosis or mild fibrosis; F2-F3: moderate or severe fibrosis; F4: cirrhosis; DC: decompensated cirrhosis; HCC: hepatocellular carcinoma; LTX: liver transplantation. SVR: sustained virological response.  \* PSA: probabilistic sensitivity analysis. In gamma (γ) distributions, parameters correspond to mean and standard deviation. | | | | |